-
Je něco špatně v tomto záznamu ?
Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy
P. Rajwa, VM. Schuettfort, F. Quhal, K. Mori, S. Katayama, E. Laukhtina, B. Pradere, RS. Motlagh, H. Mostafaei, NC. Grossmann, A. Aulitzky, A. Paradysz, PI. Karakiewicz, H. Fajkovic, K. Zimmermann, A. Heidenreich, P. Gontero, SF. Shariat
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
NLK
ProQuest Central
od 1997-02-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2000-02-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-02-01 do Před 1 rokem
- MeSH
- brachyterapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- lokální recidiva nádoru imunologie mortalita patologie chirurgie MeSH
- lymfatické uzliny patologie MeSH
- lymfocyty * MeSH
- míra přežití MeSH
- multivariační analýza MeSH
- nádory prostaty imunologie mortalita patologie chirurgie MeSH
- neutrofily * MeSH
- počet leukocytů MeSH
- počet lymfocytů MeSH
- počet trombocytů MeSH
- předoperační období MeSH
- prognóza MeSH
- proporcionální rizikové modely MeSH
- prostatektomie * MeSH
- radioterapie s modulovanou intenzitou MeSH
- retrospektivní studie MeSH
- senioři MeSH
- staging nádorů MeSH
- trombocyty * MeSH
- záchranná terapie * MeSH
- zánět krev imunologie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
PURPOSE: To examine the predictive and prognostic value of preoperative Systemic Immune-inflammation Index (SII) in patients with radio-recurrent prostate cancer (PCa) treated with salvage radical prostatectomy (SRP). MATERIALS AND METHODS: This multicenter retrospective study included 214 patients with radio-recurrent PCa, treated with SRP between 2007 and 2015. SII was measured preoperatively (neutrophils × platelets/lymphocytes) and the cohort was stratified using optimal cut-off. Uni- and multivariable logistic and Cox regression analyses were performed to evaluate the predictive and prognostic value of SII as a preoperative biomarker. RESULTS: A total of 81 patients had high preoperative SII (≥ 730). On multivariable logistic regression modeling, high SII was predictive for lymph node metastases (OR 3.32, 95% CI 1.45-7.90, p = 0.005), and non-organ confined disease (OR 2.55, 95% CI 1.33-4.97, p = 0.005). In preoperative regression analysis, high preoperative SII was an independent prognostic factor for cancer-specific survival (CSS; HR 10.7, 95% CI 1.12-103, p = 0.039) and overall survival (OS; HR 8.57, 95% CI 2.70-27.2, p < 0.001). Similarly, in postoperative multivariable models, SII was associated with worse CSS (HR 22.11, 95% CI 1.23-398.12, p = 0.036) and OS (HR 5.98, 95% CI 1.67-21.44, p = 0.006). Notably, the addition of SII to preoperative reference models improved the C-index for the prognosis of CSS (89.5 vs. 80.5) and OS (85.1 vs 77.1). CONCLUSIONS: In radio-recurrent PCa patients, high SII was associated with adverse pathological features at SRP and survival after SRP. Preoperative SII could help identify patients who might benefit from novel imaging modalities, multimodal therapy or a closer posttreatment surveillance.
Cancer Prognostics and Health Outcomes Unit University of Montreal Health Centre Montreal Canada
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology Federal Armed Services Hospital Koblenz Koblenz Germany
Department of Urology King Fahad Specialist Hospital Dammam Saudi Arabia
Department of Urology Medical University of Silesia Zabrze Poland
Department of Urology The Jikei University School of Medicine Tokyo Japan
Department of Urology University Hospital Cologne Cologne Germany
Department of Urology University Hospital Zurich Zurich Switzerland
Department of Urology University Medical Center Hamburg Eppendorf Hamburg Germany
Department of Urology University of Texas Southwestern Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
Institute for Urology and Reproductive Health Sechenov University Moscow Russia
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
Research Center for Evidence Based Medicine Tabriz University of Medical Sciences Tabriz Iran
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22012182
- 003
- CZ-PrNML
- 005
- 20220506130219.0
- 007
- ta
- 008
- 220425s2021 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00345-021-03715-4 $2 doi
- 035 __
- $a (PubMed)33997919
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Rajwa, Pawel $u Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, Medical University of Silesia, Zabrze, Poland $1 https://orcid.org/0000000340736584
- 245 10
- $a Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy / $c P. Rajwa, VM. Schuettfort, F. Quhal, K. Mori, S. Katayama, E. Laukhtina, B. Pradere, RS. Motlagh, H. Mostafaei, NC. Grossmann, A. Aulitzky, A. Paradysz, PI. Karakiewicz, H. Fajkovic, K. Zimmermann, A. Heidenreich, P. Gontero, SF. Shariat
- 520 9_
- $a PURPOSE: To examine the predictive and prognostic value of preoperative Systemic Immune-inflammation Index (SII) in patients with radio-recurrent prostate cancer (PCa) treated with salvage radical prostatectomy (SRP). MATERIALS AND METHODS: This multicenter retrospective study included 214 patients with radio-recurrent PCa, treated with SRP between 2007 and 2015. SII was measured preoperatively (neutrophils × platelets/lymphocytes) and the cohort was stratified using optimal cut-off. Uni- and multivariable logistic and Cox regression analyses were performed to evaluate the predictive and prognostic value of SII as a preoperative biomarker. RESULTS: A total of 81 patients had high preoperative SII (≥ 730). On multivariable logistic regression modeling, high SII was predictive for lymph node metastases (OR 3.32, 95% CI 1.45-7.90, p = 0.005), and non-organ confined disease (OR 2.55, 95% CI 1.33-4.97, p = 0.005). In preoperative regression analysis, high preoperative SII was an independent prognostic factor for cancer-specific survival (CSS; HR 10.7, 95% CI 1.12-103, p = 0.039) and overall survival (OS; HR 8.57, 95% CI 2.70-27.2, p < 0.001). Similarly, in postoperative multivariable models, SII was associated with worse CSS (HR 22.11, 95% CI 1.23-398.12, p = 0.036) and OS (HR 5.98, 95% CI 1.67-21.44, p = 0.006). Notably, the addition of SII to preoperative reference models improved the C-index for the prognosis of CSS (89.5 vs. 80.5) and OS (85.1 vs 77.1). CONCLUSIONS: In radio-recurrent PCa patients, high SII was associated with adverse pathological features at SRP and survival after SRP. Preoperative SII could help identify patients who might benefit from novel imaging modalities, multimodal therapy or a closer posttreatment surveillance.
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a trombocyty $7 D001792
- 650 _2
- $a brachyterapie $7 D001918
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a zánět $x krev $x imunologie $7 D007249
- 650 _2
- $a počet leukocytů $7 D007958
- 650 _2
- $a lymfatické uzliny $x patologie $7 D008198
- 650 _2
- $a počet lymfocytů $7 D018655
- 650 12
- $a lymfocyty $7 D008214
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a multivariační analýza $7 D015999
- 650 _2
- $a lokální recidiva nádoru $x imunologie $x mortalita $x patologie $x chirurgie $7 D009364
- 650 _2
- $a staging nádorů $7 D009367
- 650 12
- $a neutrofily $7 D009504
- 650 _2
- $a počet trombocytů $7 D010976
- 650 _2
- $a předoperační období $7 D057234
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a proporcionální rizikové modely $7 D016016
- 650 12
- $a prostatektomie $7 D011468
- 650 _2
- $a nádory prostaty $x imunologie $x mortalita $x patologie $x chirurgie $7 D011471
- 650 _2
- $a radioterapie s modulovanou intenzitou $7 D050397
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a záchranná terapie $7 D016879
- 650 _2
- $a míra přežití $7 D015996
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Schuettfort, Victor M $u Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Quhal, Fahad $u Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia
- 700 1_
- $a Mori, Keiichiro $u Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
- 700 1_
- $a Katayama, Satoshi $u Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
- 700 1_
- $a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
- 700 1_
- $a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Währinger Gürtel 18-20, 1090, Vienna, Austria
- 700 1_
- $a Motlagh, Reza Sari $u Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- 700 1_
- $a Mostafaei, Hadi $u Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
- 700 1_
- $a Grossmann, Nico C $u Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, University Hospital Zurich, Zurich, Switzerland
- 700 1_
- $a Aulitzky, Andreas $u Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Währinger Gürtel 18-20, 1090, Vienna, Austria
- 700 1_
- $a Paradysz, Andrzej $u Department of Urology, Medical University of Silesia, Zabrze, Poland
- 700 1_
- $a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada
- 700 1_
- $a Fajkovic, Harun $u Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria
- 700 1_
- $a Zimmermann, Kristin $u Department of Urology, Federal Armed Services Hospital Koblenz, Koblenz, Germany
- 700 1_
- $a Heidenreich, Axel $u Department of Urology, University Hospital Cologne, Cologne, Germany
- 700 1_
- $a Gontero, Paolo $u Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Turin, Italy
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Währinger Gürtel 18-20, 1090, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. shahrokh.shariat@meduniwien.ac.at $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, Weill Cornell Medical College, New York, NY, USA. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. shahrokh.shariat@meduniwien.ac.at
- 773 0_
- $w MED00004739 $t World journal of urology $x 1433-8726 $g Roč. 39, č. 10 (2021), s. 3771-3779
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33997919 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130211 $b ABA008
- 999 __
- $a ok $b bmc $g 1789678 $s 1163383
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 39 $c 10 $d 3771-3779 $e 20210517 $i 1433-8726 $m World journal of urology $n World J Urol $x MED00004739
- LZP __
- $a Pubmed-20220425
